Other languages Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
4.94 ^USD	+14.09%		-5.54%	-61.83%

04-16	Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-11	North American Morning Briefing : Stock Futures -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	04-09
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	04-07
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer	02-16
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	02-01
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives	01-31
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	01-17
Windtree Therapeutics, Inc. Announces Reduction in Arrythmias in a New Study With Istaroxime And A Pure SERCA2a Activator	01-02
Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	12-18
Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer	28/08/23
Windtree Therapeutics Secures US Patent Covering Product Candidates Aimed to Treat Heart Failure Patients	23/08/23
Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators	16/08/23
Windtree Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23
Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors	27/06/23
Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Windtree Therapeutics Closes $12.4 Million Public Offering	25/04/23
Top Midday Decliners	20/04/23
Top Premarket Decliners	20/04/23
Windtree Therapeutics Chair James Huang Resigns; Shares Sink Premarket	19/04/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Other languages

Filters